EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPTBiotechnology
+$0.26 today
- Market cap
- $250.69M
- Beta
- 1.75
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$3.16
Volume 2.75M
Average 0.95M
EYPT Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
EyePoint Pharmaceuticals, Inc.NASDAQ: EYPT
Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026
Deferred revenue remains negative
Q1 FY2026 deferred revenue was $0, compared with $5.12M a year earlier.
Context
- Deferred revenue amounted to 0.0% of total assets at the end of Q1 FY2026, down 1.4 pp from a year earlier.
- Deferred revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether deferred revenue keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 17.78M | -53.9% |
| FY2023 | 2023-12-31 | 38.59M | +3102.7% |
| FY2022 | 2022-12-31 | 1.21M | +12.7% |
| FY2021 | 2021-12-31 | 1.07M | — |
Deferred Revenue vs competitors
How EYPT compares with its peers on the latest reported figures
- EYPT's Mar 2026 deferred revenue of $0 is the 5th highest of the 11 companies compared; the peer median is $0.
- Its year-over-year change of -100.0% is the lowest of 4, against a peer median of -10.9%.
- Deferred revenue amounts to 0.0% of total assets for EYPT, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
SEPNSepterna, Inc. | Sep 2026 | $75.96M | — | — | 12.3% |
| Mar 2026 | $47.7M | +16.8% | — | 7.3% | |
| Aug 2026 | $8.61M | -66.9% | -22.4% | 0.7% | |
| Mar 2026 | $7.32M | -10.9% | — | 2.5% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Sep 2026 | $0 | — | — | 0.0% | |
| Sep 2026 | $0 | — | — | 0.0% | |
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding EYPT) | $0 | -10.9% | -22.4% | 0.0% | |
Competitors are the stored peer set for EYPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 178.59M | 95.63M | 281.26M | 99.7M | 101.82M |
| Short-term Investments | 32.97M | 48.93M | 49.79M | 271.21M | 204.27M |
| Net Receivables | 18.35M | 15.5M | 805K | 607K | 651K |
| Inventory | 3.62M | 2.89M | 3.91M | 2.31M | 1.81M |
| Other Current Assets | 517K | 782K | 1.01M | 1.41M | 20.11M |
| Total Current Assets | 237.75M | 172.81M | 344.8M | 383.31M | 328.66M |
| Property, Plant & Equipment (Net) | 2.73M | 7.4M | 10.23M | 29.18M | 20.22M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 22.75M | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 150K | 150K | 150K | 5.98M | 15.12M |
| Total Non-current Assets | 25.63M | 7.55M | 10.38M | 35.16M | 35.34M |
| Total Assets | 263.37M | 180.36M | 355.18M | 418.47M | 364M |
| Account Payables | 7.39M | 5.92M | 6.5M | 11.72M | 10.49M |
| Short-term Debt | 0 | 10.48M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 1.07M | 1.21M | 38.59M | 17.78M | 0 |
| Other Current Liabilities | 7.32M | 9.52M | 13.28M | 13.27M | 16.67M |
| Total Current Liabilities | 23.66M | 34.54M | 63.26M | 49.05M | 37.02M |
| Long-term Debt | 36.56M | 29.31M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 14.56M | 13.56M | 20.69M | 10.85M | 0 |
| Other Non-current Liabilities | 2.35M | 600K | 0 | 205K | 87K |
| Total Non-current Liabilities | 55.33M | 49.45M | 25.6M | 32.92M | 20.86M |
| Total Liabilities | 78.99M | 83.99M | 88.86M | 81.96M | 57.88M |
| Common Stock | 34K | 34K | 49K | 68K | 83K |
| Retained Earnings | (569.1M) | (671.35M) | (742.15M) | (873.02M) | (1.1B) |
| Accumulated OCI | 841K | 786K | 864K | 1.03M | 961K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 184.38M | 96.37M | 266.32M | 336.5M | 306.11M |
| Total Debt | 39.2M | 46.35M | 4.91M | 21.86M | 20.77M |
| Net Debt | (139.39M) | (49.29M) | (276.36M) | (77.85M) | (81.05M) |
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
Intrinsic Alpha fair value
Locked
Current Price
$2.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.